ROS1 and non-small cell lung carcinoma: Another study called AK104-IIT-018 (NCT05816499) included patients with histologically or cytologically confirmed stage IIIB/IIIC or IV NSCLC without sensitizing EGFR/ALK/ROS1 mutations, who must have progressed during or after a PD-1/L1 inhibitor and platinum-based chemotherapy and were treated with three-drug combination therapy (cadonilimab plus anilotinib plus docetaxel) (85).